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Linlin Xu 
 
CD166 MODULATES DISEASE PROGRESSION AND OSTEOLYTIC DISEASE 
IN MULTIPLE MYELOMA  
 
Multiple myeloma (MM) is an incurable malignancy characterized by the 
proliferation of neoplastic plasma cells in the bone marrow (BM) and by multiple 
osteolytic lesions throughout the skeleton. We previously reported that CD166 is 
a functional molecule on normal hematopoietic stem cells (HSC) that plays a 
critical role in HSC homing and engraftment, suggesting that CD166 is involved 
in HSC trafficking and lodgment. CD166, a member of the immunoglobulin 
superfamily capable of mediating homophilic interactions, has been shown to 
enhance metastasis and invasion in several tumors. However, whether CD166 is 
involved in MM and plays a role in MM progression has not been addressed. We 
demonstrated that a fraction of all human MM cell lines tested and MM patients’ 
BM CD138+ cells express CD166. Additionally, CD166+ cells preferentially home 
to the BM of NSG mice. Knocking-down (KD) CD166 expression on MM cells 
with shRNA reduced their homing to the BM. Furthermore, in a long-term 
xenograft model, NSG mice inoculated with CD166KD cells showed delayed 
disease progression and prolonged survival compared to mice receiving mock 
transduced cells. To examine the potential role of CD166 in osteolytic lesions, we 
first used a novel Ex Vivo Organ Culture Assay (EVOCA) which creates an in 
vitro 3D system for the interaction of MM cells with the bone microenvironment. 
 
vi 
EVOCA data from MM cells lines as well as from primary MM patients’ CD138+ 
BM cells demonstrated that bone osteolytic resorption was significantly reduced 
when CD166 was absent on MM cells or calvarial cells. We then confirmed our 
ex vivo findings with intra-tibial inoculation of MM cells in vivo. Mice inoculated 
with CD166KD cells had significantly less osteolytic lesions. Further analysis 
demonstrated that CD166 expression on MM cells alters bone remodeling by 
inhibiting RUNX2 gene expression in osteoblast precursors and increasing 
RANKL to OPG ratio in osteoclast precursors. We also identified that CD166 is 
indispensable for osteoclastogenesis via the activation of TRAF6-dependent 
signaling pathways. These results suggest that CD166 directs MM cell homing to 
the BM and promotes MM disease progression and osteolytic disease. CD166 
may serve as a therapeutic target in the treatment of MM.  
 
                                                                                 Edward F. Srour, Ph.D., Chair 
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Chapter 1. Introduction 
 
Hematopoiesis – B cell development 
 
The development of B cells from hematopoietic precursors is a well-organized 
process.  B cell development starts in the fetal liver during embryonic life and 
continues in the bone marrow throughout our lives. The first phase of B cell 
differentiation in the bone marrow is antigen-independent and involves progenitor 
B cell proliferation and V-(D)-J gene rearrangement (1,2). B cells are derived 
from lymphoid progenitor cells. Cytokines secreted from bone marrow stromal 
cells induce TdT and recombinase (RAG-1 and RAG-2) synthesis in lymphoid 
progenitors. The cells then undergo VH and DH recombination and become early 
pro-B cells. VH, DH, and JH rearrangements of the heavy chain complete the 
process of the late pro-B cell stage.  
 
When Pro-B cells express membrane µ chains with surrogate light chains, they 
become pre-B cells. Pre-B receptor complex also includes Igα and Igβ signal 
transduction molecules, which have ITAMs (immune-receptor tyrosine activation 
motifs) (3) that become phosphorylated in response to antigen-BCR binding. 
Antigen binding stops the cells from H chain recombination and promotes them 
to proliferate into B cell clones with the same µ chain. After proliferation, VL-JL of 
the light chain gene segments undergo rearrangements and the cells with VL-JL 
rearrangements become immature B cells. This is a repertoire of B cell clones 
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with a wide range of immunoglobulin variable regions capable of recognizing 
different antigens (4). 
 
The second phase of B cell development is antigen-dependent and occurs 
following B cell activation by antigen binding and co-stimulation. In this stage, B 
cells either differentiate into memory B cells or terminal and antibody-secreting 
plasma cells (1). Plasma cells are the final differentiation stage of B cells. 
 
General overview of multiple myeloma 
 
Multiple myeloma (MM) is a plasma cell malignancy. It is characterized by two 
main features: malignant plasma cells that infiltrate and grow in the bone marrow 
and development of a progressive osteolytic bone disease (5). MM is the second 
most frequent hematological cancer in the US with a higher incidence rate 
among African Americans. According to the American Cancer Society, there are 
around 26,000 new cases of MM and 11,000 deaths from MM in the United 
States each year. MM is usually diagnosed at a later stage in life predominantly 
among aged individuals and men are slightly more likely to get MM than women. 
In the US, MM is almost twice as common among African Americans as it is 
among whites and being overweight or obese is another risk factor for MM.  
Plasma cell monoclonal gammopathy of undetermined significance (MGUS) is 
the precondition of MM (6). MGUS has no symptoms and is usually characterized 
by excess paraproteins produced by plasma cells. While in MGUS, the plasma 
3 
cells is not malignant and MGUS is not associated with bone lesions. Around 
20% of patients with MGUS will progress to MM throughout their lives (7).   
 
MM is characterized by several features, including the following: 
 
Bone disease 
Up to 90% of MM patients develop bone disease and it is the most common 
symptom in MM. MM bone disease is caused by the increased activity of 
osteoclast and decreased activity of osteoblast and bone resorption also leads to 
the release of calcium to the blood, causing hypercalcemia and other related 
symptoms. Bone lesions can be evaluated by x-ray or CT scan.   
 
Anemia 
The anemia in MM results from the overgrowth of malignant cells in the BM and 
the inhibition of normal red blood cell proliferation.  
 
Kidney failure 
Kidney failure in MM is mainly caused by excessive immunoglobulins produced 
by MM cells. The hypercalcemia caused by increased bone resorption can also 
contribute to kidney failure.  
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Table 1.  Paraproteins and light chains secreted by MM cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line Paraprotein+ light 
chain 
NCI-H929 IgA kappa 
RPMI8226 lambda light chain 
MM1.S lambda-light chain 
OPM2 IgG lambda 
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Infection 
Infection in MM is due to the immune deficiency. Normal plasma cells that can 
secrete antibodies to fight infections are inhibited by the MM malignant plasma 
cells, which do not produce infection-fighting antibodies and thus do not protect 
against infections.  Although much effort has been made for effective treatments 
and supportive care of MM, it is still incurable. Fortunately, the prognosis and 
survival of MM patients improved slightly over the last several decades (8).  In 
MM, the proliferation of clonal malignant plasma cells in the bone marrow (BM) is 
usually accompanied by the secretion of monoclonal immunoglobulins 
(paraproteins) that can be detected in the serum or urine of the patients (9).  
Table 1 describes the paraproteins and light chains secreted by the commonly 
used MM cells lines. 
 
Different MM clones may secrete different immunoglobulins, which makes it 
difficult to enrich MM cells from MM patients for research in the laboratory. 
However, the development of flow cytometry (FC) provided more accurate and 
sensitive methods to examine plasma cell populations. Traditionally, FC analysis 
identified CD38+CD45-/dim as MM cells (10,11). However, this gating strategy 
greatly excludes MM cells that are CD45+. CD138 (sydecan-1) is a 
transmembrane heparin sulfate proteoglycan that is involved in several cellular 
functions including cell binding, cell proliferation and cell migration (12,13). 
Studies have shown that CD138 is expressed on plasma cells and MM 
neoplastic plasma cells but not on T and B cells (14). Thus CD138 is considered 
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as the most specific marker for plasma and neoplastic plasma cells. The 
advances of multi-parameter FC and monoclonal CD138 antibody made it 
feasible to evaluate the expressions of CD45, CD38 and CD138 on MM cells. FC 
analysis with 306 MM patients’ BM samples showed that CD138 can be used as 
a selection marker of MM patients’ BM plasma cells (15). Most laboratories are 
now applying this method to enrich MM BM cells. 
 
While CD138 produces very good results with fresh cells, it does not work well on 
later processed or frozen samples due to the fact that CD138 tends to shed 
rapidly from the cell surface (15,16). Using computational screen for MM plasma 
cell markers, CD319 and CD269, both are highly and only expressed on the 
surface of MM plasma cells compared to any major hematopoietic cell types, 
have been suggested as new enrichment markers for MM patients’ BM cells (17). 
However, nowadays, most laboratories are still using CD138 to enrich fresh MM 
BM cells for research purpose since it is easier to get the antibodies for CD138. 
 
Multiple myeloma and bone marrow microenvironment 
 
MM is a hematological malignancy with neoplastic plasma cells accumulating 
and proliferating in the BM. The BM microenvironment is essential for MM cell 
survival and growth. The BM microenvironment is a complex milieu of cells and 
non-cellular components that interact together to sustain normal hematopoietic 
stem cell (HSC) survival and the HSC pool. This microenvironment contains 
extracellular matrix proteins such as fibronectin and collagen and multiple types 
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of “stromal” cells including macrophages, fibroblasts, osteoblasts, osteoclasts, 
endothelial cells (EC), immune cells, and mesenchymal stem cells (MSC) in 
addition to HSC and hematopoietic precursors. Interactions between MM cells 
and the BM microenvironment enable MM cells to modulate the 
microenvironment and make it favorable for the maintenance of MM cell survival, 
growth and proliferation as well as their drug resistance(18,19).  
 
Extracellular Matrix (ECM) 
Essentially, “stromal” cells are the main source of the BM ECM, which includes 
fibronectin, laminins, collagens and proteoglycans. These ECM proteins 
participate in cell adhesion, proliferation, migration and angiogenesis which are 
important for tumor development. Several reports suggested the involvement of 
ECM proteins in tumor expansion and their drug resistance (20,21) and provides 
a protective microenvironment for MM cells against chemotherapy (23,24). ECM 
remodeling plays a key role in MM homing and progression. Metalloproteinases, 
a family of proteinases, can degrade the ECM proteins to help MM migration 
(22). Angiogenesis is also critical for MM progression (25). MM cells interact with 
ECM proteins and induce the production of angiogenic cytokines to further 
induce angiogenesis.  
 
Cytokines and Chemokines 
The growth and proliferation of MM cells are also affected by various cytokines, 
including interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), 
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hepatocyte growth factor (HGF), transforming growth factor-beta (TGF-β) and 
other factors.  
 
IL-6 was shown to affect the growth of MM cells and can increase the survival of 
MM cells by blocking apoptosis (26). VEGF is a critical cytokine that is actively 
involved in angiogenesis (27) and is expressed by both MM cell lines and primary 
MM BM cells (28). HGF is also a potent growth and survival factor for MM 
expressed by MM cell lines and primary MM cells (29). TGF-β can be secreted 
by MM cells, BM stromal cells and osteoblasts to induce the secretion of other 
factors and to promote osteoclastogenesis (30). Chemokines and their receptors 
(31) are vital in MM cell homing to the BM, growth and bone destructions. The 
expression of chemokine receptors such as CXCR4, CCR1, and CXCR7 in 
myeloma cells has been shown to be correlated with myeloma disease 
progression and patients’ survival (32,33). The role of CXCR4 in myeloma cell 
homing has been well studied (34). Studies have shown that the CXCR4 
inhibitor, AMD3100 can increase the sensitivity of myeloma cells to drug 
treatment through disrupting myeloma cells and BM microenvironment 
interactions (35).  
 
Bone marrow niche cells 
As a hematopoietic malignancy in the BM, the interactions between MM cells and 
bone marrow stromal cells are critical for MM cell survival and proliferation. 
Macrophages, an abundant cellular component of the BM niche, were shown to 
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support MM cell growth through increasing MM cell proliferation and decreasing 
MM cell apoptosis (36). Furthermore, tumor-associated macrophages heavily 
infiltrate the BM of MM patients and the direct contact between macrophages and 
MM cells plays a vital role in MM drug resistance and survival (37). EC are 
another important component in the BM niche. Blood vessels are essential in the 
tumor microenvironment to facilitate tumor migration and metastasis. In MM, 
endothelial cells secrete chemokines to mediate the interactions between 
endothelial cells and MM cells and further promote MM cell proliferation (38). 
Endothelial cells in MM express specific antigens to participate in angiogenesis 
and vasculogenesis to enhance MM dissemination (39).  
 
Multiple myeloma bone disease 
 
Up to 90% of MM patients develop bone disease, which not only affect patients’ 
quality of life, but also their longevity. MM bone disease is characterized by 
multiple osteolytic lesions throughout the skeleton, suggesting that trafficking of 
MM cells from the BM and lodgment of these cells at secondary sites is important 
for disease progression. During bone turnover, osteoblasts are responsible for 
the formation of new bone while osteoclasts are the cells responsible for bone 
resorption. Normally, bone turnover is balanced by osteoblasts and osteoclasts 
activities. However, in MM patients, this balance is broken by increased 
osteoclasts activity and decreased osteoblasts activity.  
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Osteoblasts are fully differentiated cells from MSC. Runt-related transcription 
factor 2 (RUNX2) is the key transcription factor in osteoblastogenesis. The 
commitment of mesenchymal stem cells to osteoblasts differentiation depends on 
the proper RUNX2 expression (40). RUNX2 -/- mice results in the lack of a 
mineralized skeleton and the absence of RUNX2 functions results in bone 
defects (41,42). During osteoblastogenesis (Figure 1), the expression of RUNX2 
closely regulates a complex gene-regulatory network (43-45); whereby the 
expression of Runx2 upregulates a variety of osteoblasts lineage-specific genes 
including Osx (osterix), Ocn (osteocalcin), and Bsp (bone sialoprotein), and 
concomitantly downregulates the expression of non-osteoblasts genes such 
as the adipogenic gene PPAR-γ (peroxisome proliferator-activated receptor 
gamma) and the myogenic gene MyoD.  In MM, Osteoblastogenesis and 
osteoblasts differentiation are impaired through the downregulation of RUNX2 
activity by myeloma cells (46). The downregulation of RUNX2 activity further 
leads to the repression of Ocn, Bsp and alkaline phosphatase (ALP) gene 
expression which ultimately result in suppressed bone formation in MM. 
 
Osteoclasts are multi-nucleated cells derived from the hematopoietic monocyte-
macrophage linage. Receptor activator of nuclear factor kappa-B ligand 
(RANKL) and its receptor RANK are essential modulators in osteoclast 
maturation and activation. During normal osteoclastogenesis, RANKL, produced 
by osteoblasts, binds to RANK on osteoclast precursors and leads to osteoclast 
differentiation. Macrophage colony-stimulating factor (M-CSF), another important 
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cytokine secreted by osteoblasts, binds to its receptor on osteoclast precursors, 
and promotes osteoclast maturation (47). Osteoprotegerin (OPG) is the decoy 
receptor of RANKL which, upon binding to RANK alters the availability of the 
later to promote osteoclastogenesis. The balance between RANKL and OPG or 
the ratio of RANKL to OPG controls osteoclast formation and maturation (Figure 
2). When this ratio is high, there is an increased osteoclastogenesis and when it 
is low, there is a decreased osteoclastogenesis. MM cells promote the secretion 
of RANKL from osteoblast and it has also been reported (48) in some cases that 
MM cells themselves secreted RANKL, leading to an increased RANKL to OPG 
ratio and resulting in the osteoclast formation.  
 
Several signaling pathways are involved in MM induced- 
osteoclastogenesis.  Tumor necrosis factor (TNF) receptor-associated factor 6 
(TRAF6), an E3 ubiquitin ligase, is a crucial adaptor protein in the formation of 
osteoclast (49).   TRAF6 deficient mice have defective osteoclast activity 
(50,51). Activation of TRAF6 by upstream signaling activates downstream 
signaling pathways including NFkB, PI3K/AKT and MAPK pathways (52,53). 
These pathways further lead to the upregulation of key modulators in 
osteoclastogenesis and results in osteoclast formation and differentiation (Figure 
3). TRAF6 signaling has been shown to be activated in MM by several 
investigators (54,55), providing a therapeutic target in the treatment of MM.  
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Figure 1.  Schematic representation of MSC differentiation 
Osteoblasts, chondrocytes and adipocytes differentiate from a common pluripotent 
precursor, the MSC. A number of regulators control MSC lineage fate. RUNX2 is 
the key transcription factor for osteoblasts differentiation.  
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15 
Figure 2. Osteoclastogenesis     
RANKL expressed on stromal cells or osteoblast binds to RANK on osteoclast 
precursors, leading to osteoclastogenesis. OPG is a decoy receptor for RANKL. 
The binding of OPG to RANKL blocks RANK binding, resulting in decreased 
osteoclastogenesis. M-CSF is also expressed by stromal cells/osteoblasts. The 
binding of M-CSF to its receptor c-Fms on osteoclast precursors, also leads to 
osteoclast differentiation.  
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Multiple myeloma stem cell controversy 
 
The concept of cancer stem cells (CSC) hypothesizes that a small population of 
cancer cells is responsible for the initiation and proliferation of cancer (56). 
Compared to normal stem cells, CSC are not only predicted to be clonogenic, 
but also drug resistant. CSC express proteins such as anti-alkylating enzymes 
like aldehyde dehydrogenase (ALDH) (57) to neutralize therapeutic drugs or 
members of the ATP-binding cassette (ABC) family of transporters (58) that 
pump the therapeutic agents out of the cells.  
 
Despite therapeutic advances, MM remains incurable due to relapse and 
therapy-refractory disease. Persistence of drug-refractory MM stem cells 
(MMSC) provides a possible explanation for this clinical outcome. Targeting  
these cells is therefore appealing in MM therapy and prompted a search for 
MMSC. However, contradictory results about MMSC phenotype have been 
obtained. Studies by the group of Matsui in John Hopkins established the 
composite phenotype of CD45+CD34-CD138-CD38+CD19+CD27+ cells as a 
population enriched in MMSC (59). Essentially, a rare cell population 
phenotypically similar to normal memory B cells (CD20+CD27+) but lacking 
CD138 are the long term proliferating MM cells (60). In contrast to CD138-
positive cells, CD138 negative cells could initiate tumor in NOD-SCID mice and 
differentiate into CD138 positive myeloma cells. Further research on these cells 
demonstrated that they express proteins to detoxify therapeutic drugs and efflux 
the drugs out of the cells. However, studies by other groups raise controversy 
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regarding the true nature of cells with this phenotype. Quesnel et al (61)showed, 
in both patients and MM cell lines, CD34+CD138+B7-H1 cells are clonogenic 
MM cells and MM cells with this phenotype can initiate myeloma in NOD-SCID 
mice.  The ability to efflux Hoechst 33342 by the ATP-binding cassette protein 2 
(ABCG) and/or ATP-binding cassette transporter 1 (ABCT) identifies a subset of 
cells from normal and malignant tissues—side population (SP) cells (62,63) 
which display stem cell properties.  Several groups have identified SP cells in 
human MM cell lines and patient samples using Hoechst 33342 staining. 
However, Matsui and co-workers identified SP cells within the CD138- MM 
subpopulation while Quesnels demonstrated that the clonogenic SP cells in MM 
expressed CD138. Moreover, Yaccoby et al (64) using SCID mice implanted 
with human fetal bone fragments (SCID-hu mice), showed that 
CD38highCD45negMM cells can repopulate in the implanted bone and self-renew 
in secondary SCID-hu recipient mice (65).  
 
Due to the differences in stem cell purification protocols and mice models 
employed to test the properties of the putative CSC, there is a major controversy 
regarding the phenotype of MMSC. To definitely confirm the stemness 
characteristics of certain phenotype of MM populations, in vitro and in vivo 
assays at signal cell level should be investigated.  
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Figure 3.  TRAF6 signaling in osteoclastogenesis 
In osteoclast precursors, the binding of TRAF6 upstream signaling, such as 
RANKL to RANK, leads to the activation of TRAF6. The activation of TRAF6 
leads to the activation of the downstream pathways, such as Akt, p38/MAPK and 
NFkB. These signals activates NFATc1, which is a key modulator in 
osteoclastogenesis, leading to osteoclast differentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
CD166 
 
Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a member of the 
immunoglobulin superfamily with five extracellular immunoglobulin-like domains 
(VVC2C2C2), a transmembrane region, and a short cytoplasmic tail. huCD166 
gene was located on human chromosome 3q13.1-q13.2(66). CD166 is capable 
of mediating both homophilic interactions with CD166 and heterophilic 
interactions with CD6 (Figure 4), which is expressed on the outer membrane of 
T-lymphocytes and other immune cells and important for T cells activation 
(67,68). The CD6 binding site of CD166 is located on CD166 N-terminal domain 
(69) and all the residues critical for CD6 binding are conserved between human 
and murine CD166 demonstrated by mutagenesis studies by Bowen et al (70). 
As the binding of CD6, homophilic interactions of CD166 is also happening in N-
terminal domain (67). There is competition between heterophilic and homophilic 
interaction as shown by mass spectrometry analysis(69).  The expression of 
CD166 is conserved across species (71) with 90% homology between murine 
and human (70), suggesting that CD166 from both species can interact with 
each other and modulate cell activities from mouse or human. CD166 is involved 
in various physiologic and pathologic processes including cell adhesion, cell 
migration, and hematopoiesis and tumor progression (72,73). Recent studies 
demonstrated that the expression of CD166 is positively correlated with disease 
progression in several cancer models including breast cancer and melanoma. In 
breast cancer, CD166 is crucial for breast cancer cell survival by inhibition of cell 
death (74). In melanoma, CD166 is important for melanocytic tumor progression 
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and metastasis (75,76). The levels of CD166 expression on tumor cells is 
positively correlated with the prognosis.  
 
CD166 has been demonstrated as a cancer stem cell (CSC) marker, including 
colon CSC  and prostate CSC (77). In prostate cancer, CD166+ TRA-1-
60+CD151+ CSCs can form spheres in vitro and initiate tumor formation in vivo. 
CD166 also identifies a population of multipotent colon CSC. The function of 
CD166 in tumors is related to adhesive properties based on homophilic 
interactions. 
 
The expression of CD166 on stem/progenitor cells and its role in hematopoiesis 
have been described in several studies. Our laboratory has shown that CD166 is 
a functional marker on HSC and the expression of CD166 on HSC is critical for 
their homing to the BM and engraftment (78). Beside the expression of CD166 
on hematopoietic stem/progenitor cells, it is also expressed on hematopoietic 
stem cell niche cells including MSC, osteoblast, endothelial cells (68,79), 
indicating that the hemophilic interactions mediated by CD166 may be essential 
for the maintenance of the hematopoietic stem cell pool.  
 
How CD166 is regulated is not well known. In hepatoma cells, CD166 and miR9-
1 are identified as the targets of NFkB. Under serum starvation condition, NFkB 
activation upregulated CD166 transcription. However, miR9-1 upregulation by 
NFkB was delayed, resulting in the repression of CD166 translation through its 
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target sites in the 3′-UTR of CD166 mRNA, forming a negative regulatory loop 
downstream of NFkB (80).   Gilsanz et al (81) reported that the tetraspanin 
CD9 can augment CD166 clustering and upregulate CD166 surface expression 
to promote CD166 adhesive function.  
 
Goals of Research 
 
While the role CD166 plays in hematopoiesis has been extensively studied, it is 
only in the last few years that researchers have begun to appreciate the role of 
CD166 in cancer and cancer stem cells. Many groups around the world have 
investigated the function of CD166 in various cancer models, including breast 
cancer and melanoma. However, the role of CD166 in MM has not been 
investigated. We previously demonstrated that CD166 plays an important role in 
sustaining the ability of osteoblasts to support the maintenance and function of 
HSC. We also recently reported that CD166 is an important molecule on normal 
murine and human HSC and is critical for HSC homing to the BM and 
engraftment. Interestingly, our studies demonstrated that CD166 is a functional 
marker on normal HSC and osteoblasts since CD166- HSC engrafted poorly in 
normal hosts and the microenvironment of CD166- KO mice did not support the 
long-term engraftment of normal HSC. Taken together, these data prompted us 
to investigate whether CD166 is involved in the trafficking of MM cells or in 
modulating MM disease progression and osteolytic diseases.  
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Figure 4. CD166-CD6 interactions between cells 
CD6 contains three SRCR domains (Sc, squares) and CD166 contains five IgSF 
domains (two V and three C2). The membrane proximal domain of CD6 binds the 
N-terminal immunoglobulin superfamily (IgSF) domain of CD166. 
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Chapter 2. Expression of CD166 on MM cells and the Role of CD166 in Cell 
Migration to the BM 
 
Introduction 
 
CD166 is a member of the immunoglobulin superfamily that mediates both 
heterophilic CD6-CD166 and homophilic CD166-CD166 interactions. The amino 
acid sequences of human CD166 (huCD166) and murine CD166 (mCD166) 
display an overall identity of 93% (70). Besides being involved in multiple 
biological processes, CD166 is overexpressed in various tumor models, such as 
invasive melanoma, breast cancer and prostate carcinoma, and is an 
independent prognostic marker for several cancers (82). However, whether or 
not CD166 is involved in myeloma disease progression has not been 
investigated.  
 
Myeloma is characterized by multiple lytic lesions throughout the skeleton. 
Studies also show that MM cells can be detected in the PB (83). These 
observations indicate that MM cells may disperse from their place of origin and 
cause osteolytic lesions at multiple sites throughout the skeleton, and MM cells 
have the capacity to traffic from BM to the PB and (re)lodge at secondary sites in 
the BM (homing). Similar to the migration and homing process of normal 
leukocytes, BM homing of MM cells is mediated by multiple adhesion molecules 
through a multistep process. Although several studies have investigated the 
mechanisms of MM homing (84,85), mechanisms of trafficking and homing of 
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MM cells into the BM microenvironment and MM pathogenesis have not been 
well understood.  
 
As an adhesion molecule, CD166 has been shown to be involved in metastasis 
in several cancer models, including breast cancer and melanoma (74-76). We 
have recently reported that CD166 is an important molecule on normal HSC from 
murine and human hematopoietic tissues and plays a critical role in HSC homing 
to the BM and engraftment (78,86).  In this chapter, we first examined the 
expression of CD166 on MM cell lines and MM patient cells. Then we assayed 
whether or not CD166 is involved in MM homing and disease progression.  
 
Materials and Methods 
 
Cells, cell culture, and mice 
 
The H929 and RPMI 8226 human MM cell lines were purchased from ATCC. The 
OPM2 and JJN3 cell lines were generously provided by Dr. G. David Roodman 
(IUSM, Indianapolis, IN). CD138-positive primary myeloma cells from patients 
were kindly provided by Drs. Attaya Suvannasankha and Rebecca Silbermann 
(IUSM, Indianapolis, IN). MM cells were cultured in RPMI 1640 and were 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and 
streptomycin (P/S). All cells were maintained at 37 ℃ with 5% CO2 air. All studies 
using human cells were approved by the institutional review board of the IUSM.  
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Adult NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6- to 8-week-old), 
C57BL/6 mice and ALCAM-/- (CD166-/-) mice (6- to 8-week-old or 10-day old 
pups) were used. Mice were bred and housed in the animal facility at Indiana 
University. For MM inoculation studies, NSG mice received 275 cGy ionizing 
radiation from a cesium source followed by cell inoculation approximately 2 h 
later. All procedures were approved by the Institutional Animal Care and Use 
Committee of the IUSM and followed National Institutes of Health guidelines. 
 
MM primary BM CD138+ cell selection, flow cytometry and sorting  
 
MM primary BM CD138+ cells were selected by immunomagnetic separation 
(magnetic activated cell sorting, MACS) using anti-CD138 MicroBeads (Miltenyi 
Biotec). Briefly, MM patients’ BM mononuclear cells were enriched using Ficoll-
Paque Premium 1.084 (GE health care). Mononuclear cells were counted and 
incubated with anti-CD138 Microbeads at 10ul microbeads/1x107 cells followed 
by magnetic separation. 
 
BM cell suspensions or MM cell lines were labeled with monoclonal CD166-PE 
antibody (Biolegend). Cells were acquired on an LSRII (BD Biosciences) flow 
cytometer, and events (0.1-2x106) were collected and analyzed with FlowJo.  
CD166+ and CD166- cells were sorted on the BD FACSAria cell sorter from MM 
cell lines and patient CD138+ MM cells after staining with anti-human CD166-PE.   
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Transfection and infection studies 
 
The lentiviral vectors (pLKO1 vector with hCD166shRNA construct) to 
knockdown (KD) CD166 expression in MM cells was graciously provided by Dr. 
Helmut Hanenberg (IUSM, Indianapolis, IN). 
 
To generate lentiviral stocks, lentiviral vectors were transfected into the packing 
cell line 293T using lipofectamine 2000 (invitrogen) according to the 
manufacturer’s instructions. Viral supernatant was collected 48 h after 
transfection. H929 cells were incubated with viral supernatant for 12 h and then 
cultured in fresh RPMI1640 at 37℃ in 5% CO2 air for 72 h. GFP-positive cells 
were sorted on a BD FACSAria cell sorter.  
 
Homing assay and mice xenograft human MM model 
 
Homing of inoculated MM cells to the BM of irradiated recipients was performed 
as previously described (87-89). Briefly, 2x107H929-GFP (mock control or 
CD166KD) cells were washed with PBS and IV injected into sub-lethally 
irradiated NSG mice. Recipient mice were killed 14 h post-transplantation, and 
BM cells were recovered and analyzed for GFP-positive cells.  
 
For mice xenograft human MM model, 200ul containing 1x105 H929-GFP cells 
(mock control or CD166KD) were IV injected into sub-lethally irradiated NSG 
mice. To evaluate disease progression, blood was drawn from individual mice 
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every two weeks until 16 weeks and human IgA (huIgA)-kappa levels were 
assayed in the serum with ELISA. Mouse survival was monitored over a period of 
220 days. In a separate similar experiment with 14 mice/group, 6 mice from each 
group were euthanized at 8 weeks post-transplantation and the calvariae were 
dissected and processed for histology analysis. The other mice were monitored 
for the survival.   
 
Similarly, NSG mice were IV injected with flow sorted CD166+ or CD166- H929-
GFP/luciferase cells. After 12 weeks, mice were injected with D-Luciferin 
(Promega, 150mg/Kg mouse) sub-cutaneously and imaged with Berthold 
NightOWL LB 971 in vivo Imaging System (IUSM). 
 
Real-time PCR 
 
Total mRNA was extracted using RNeasy or QIAzol (QIAGEN) per the 
manufacturer's protocol and reverse-transcribed using SuperScript II (Invitrogen). 
Quantitative PCR was performed on an ABI7900 using a SYBR Green PCR Core 
Kit (Applied Biosystems). The primers used for quantitative PCR are listed 
in Table 2. Relative expression was calculated using the comparative 
2−ΔΔCt method, with GAPDH as the internal control. 
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Statistical analysis 
 
Each experiment was repeated at least 3 times, and all quantitative data are 
presented as mean ± SEM unless otherwise stated. Statistical differences were 
determined by Student t-test, log-rank test, one-way Analysis of 
variance(ANOVA) or two-way ANOVA with Bonferroni post t-test. Results were 
considered significantly different for p < .05. 
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Table 2.  qRT-PCR primer sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name Forward primer 
sequence (5’ to 3’) 
Reverse primer 
sequence (5’ to 3’) 
Gapdh, 
human 
AATCCCATCACCATCT
TCCA 
TGGACTCCACGAC
GTACTCA 
CD166, 
human 
CGGTCTCCTTCCAGG
ATGGT 
GCTTCCGTCAGCG
TCAACA 
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Results 
 
CD166 is expressed on MM cell lines and primary MM CD138+ cell 
 
Our laboratory previously showed that CD166 is a critical functional marker on 
HSC (78).  Since MM is a hematopoietic malignancy, we first evaluated CD166 
expression on MM cells. All four cell lines tested expressed CD166 mRNA (Figure 
5A). Flow cytometry also demonstrated five cell lines expressed varying levels of 
CD166 on the cell surface (Figure 5B). Moreover, CD166 was also expressed on 
CD138+ cells obtained from 6 MM patients (Figure 5C). More than 50% of CD138+ 
BM cells from all patients expressed CD166. However, there was no significant 
difference in the expression of four other markers including VLA-4, VLA-5, CXCR4 
and CD90 involved in the trafficking of hematopoietic cells between CD166+ and 
CD166- MM cells (Figure 6A). CD6, another molecule interacting with CD166, was 
not expressed on MM cells including MM cell lines and MM patients’ BM CD138+ 
cells, either (Figure 6B).   
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Figure 5.  CD166 is expressed on both MM cell lines and MM patients’ 
CD138+ cells  
(A) PCR analysis demonstrating CD166 expression levels on 4 MM cell lines. (B) 
Flow cytometric analysis of CD166 expression levels on 5 MM cell lines. (C) Left: 
Representative flow cytometric analysis of CD166 expression levels on MM 
patient’ CD138+ cells. Right: CD166 expression levels on 6 MM patients’ 
CD138+ cells. Percentage of CD166+ cells in each of the 6 samples is indicated 
above each bar.  
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Figure 6. The expression of other molecules on MM cells 
(A). Flow cytometric analysis demonstrated that both CD166+ H929 and CD166- 
H929 have similar expression patterns of the adhesion molecules VLA-4, VLA-5, 
CXCR4, and CD44. (B). Flow cytometric analysis demonstrated that MM cell 
lines H929 and OPM2, and two MM patient’s BM CD138+ cells are negative for 
CD6 expression. Black line = isotype, red line = sample. 
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Figure 7.  CD166+ cells preferentially home to the BM of NSG mice  
(A-B) A total of 2x107 GFP-labeled H929 cells were IV injected into sub-lethally 
irradiated NSG mice and GFP+ cells were recovered from mice BM 14h later. 
The percentage of CD166+ cells within H929 cells before injection and from BM-
homed cells were compared flow cytometrically. Data are represented as mean ± 
SEM from 3 pooled experiments (N = 3 mice/group/experiment, each assayed 
individually). Student t-test, *p<0.05). 
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CD166 is important for MM cells homing to the bone marrow of NSG mice 
 
We next examined the role of CD166 in the migration of MM cells to the BM 
using previously described homing assays (87). H929-GFP cells were injected 
into the tail vein of NSG mice and 14h post-injection, the mice were euthanized 
and the percentage of MM cells (GFP+) in the bone marrow was determined by 
flow cytometric analysis (Figure 7A). While the percentage of CD166+ H929 cells  
was originally 29.9%±1.4% in H929 cells maintained in vitro, that among BM-
homed cells increased to 80.0%±2.5% (Figure 7B, p<0.05), suggesting that 
CD166 facilitated or directed the homing of MM cells to the marrow 
microenvironment. To investigate the impact of CD166 on MM homing, we 
constructed GFP-tagged lentiviral shRNA for huCD166. This construct reduced 
the endogenous CD166 mRNA level as well as the CD166 protein level in H929 
cells up to 90% (Figure 8A-B). huCD166 shRNA-expressing H929 cells displayed 
significantly reduced (45%) homing efficiency compared with the mock control 
shRNA-expressing cells (Figure 8C-D).   
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Figure 8. CD166KD inhibits MM cells from homing to the BM 
(A) PCR assessment of the level of CD166 knockdown with lentiviral shRNA for 
huCD166. (B) Flow cytometric assessment of the level of CD166 knockdown with 
lentiviral shRNA for huCD166. (C) 2x107 GFP-labeled mock control or CD166KD 
H929 cells were iv injected into sub-lethally irradiated NSG mice. GFP cells were 
recovered from mouse BM 14h later and (D) the number of H929 cells homed to 
the BM was calculated. Data are represented as mean ± SEM from 3 pooled 
experiments (N = 3 mice/group/experiment, each assayed individually). Student 
t-test, *p<0.05. 
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Figure 9.  CD166KD on H929 cells does not alter cell growth kinetics  
Mock control or CD166KD H929 cells were cultured at a density of 1.3x104 /ml in 
RPMI1640 supplemented with 1% FBS. Cell growth was examined by counting the 
cell number at days 1, 3 and 5. Data represent three experiments and are 
expressed as mean± SEM.   
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Knockdown of CD166 on myeloma cells does not alter growth kinetics in 
vitro 
 
We assessed whether or not the expression of CD166 on H929 cells affects the 
growth kinetics of these cells. Mock or CD166KD H929 cells were seeded at a 
density of 1.3x104 /ml in RPMI1640 supplemented with 1% FBS. Cell growth was 
examined by counting the cell number. There is no significant difference of the 
growth kinetics between mock and CD166KD H929 cells (Figure 9). 
 
Homing of CD166+ MM cell to the BM of NSG mice is not dependent on the 
expression of CXCR4 
 
Previous studies by others showed that SDF-1/CXCR4 is a critical regulator of 
MM homing and SDF-1 dependent migration is regulated by the PI3K and 
ERK/MAPK pathways (84). We next examined whether or not CXCR4 is involved 
in CD166 mediated homing of MM cells to the BM. Using flow cytometry, we 
assayed the expression of CXCR4 on mock control or CD166KD H929 cells. 
Results from these analyses showed that there was no significant difference of 
CXCR4 expression levels on control H929 compare to CD166KD H929 cells 
(Figure 10A), indicating that CXCR4 may not participate in CD166 directed MM 
cell homing. We next compared the expression levels of CD166 on H929 cells in 
the PB to that on cells in the BM of NSG mice receiving H929 cells and found 
that the mean fluorescence intensity (MFI) of CD166 is significantly higher on 
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H929 cells in the BM compared to that in the peripheral blood (Figure 10B), 
indicating that CD166 is critical in directing H929 cells homing to the BM.  
 
Knockdown of CD166 on myeloma cells delays disease progression in vivo 
and enhances survival  
 
We used a xenograft model to determine the role of CD166 in initiation of MM 
and in disease progression. First, we investigated whether CD166 is important in 
initiating tumors in NSG mice. H929 GFP/luciferase cells were flow sorted into 
CD166+ and CD166- fractions which were then injected into NSG mice via IV 
injection. At 12 weeks after injection, bioluminescent imaging of the mice 
demonstrated a substantial difference in the tumor burden between mice with 
CD166+ H929 cells versus those receiving CD166- H929 cells (Figure 11A) 
demonstrating that CD166 contributed significantly to the burden of MM in these 
mice.  
 
Using shRNA, we next examined the impact of sustained suppression of CD166 
expression on the pathobiology of MM in NSG mice. NSG mice were IV injected 
with mock control shRNA or huCD166 shRNA-expressing H929 cells and 
disease progression was monitored over time. Serum levels of human IgA 
(huIgA) kappa in mice receiving mock control H929 were detected earlier and 
increased dramatically faster than in those receiving huCD166 shRNA-
expressing H929 cells (Figure 11B) reflecting increased tumor burden and rapid 
advancement of MM in the presence of CD166. Disease progression was 
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monitored over a period of 220 days and survival was plotted in a Kaplan-Meier 
survival curve (Figure 11C). NSG mice bearing CD166KD H929 cells showed a 
significant delay in disease progression and prolonged survival. 
 
NSG mice injected with CD166KD H929 cells had significantly less bone 
lesions 
 
MM is characterized by multiple lytic lesions in different areas of the bone. A 
separate cohort of mice treated similarly with mock control or CD166KD H929 
cells, was euthanized at 8 weeks post-injection to assess the severity of 
osteolytic lesions in these animals. Flow cytometric analysis showed that GFP-
labeled H929 cells can be detected in the BM from both mice transplanted with 
mock or CD166KD H929 cells (Figure 12A). Radiography demonstrated 
significantly larger osteolytic lesion areas on the tibiae in mice inoculated with 
mock control cells than with CD166KD cells (16.3±5.5mm2 vs 5±4.5mm2, 
p<0.05) (Figure 12B). Furthermore, microCT analysis of the tibiae confirmed that 
these mice had significant lower trabecular bone volume (BV/TV) fraction 
compared to those transplanted with CD166KD H929 cells (Figure 12C).  
Consistent with these results, calvariae from mice receiving CD166KD cells had 
significantly lower osteoclast numbers per bone surface (1.6±0.2) compared to 
those from mice injected with mock control H929 (4.4±1.0, p<0.05) indicated by 
TRAP staining (Figure 12D-E). On the other hand, downregulation of osteocalcin 
mRNA, an osteoblasts differentiation marker, in calvariae was decreased when 
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the mice received CD166KD H929 cells (Figure 12F). These results indicate that 
CD166 contributes directly to the pathophysiology and progression of MM.  
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Figure 10.  Homing of H929 cells to the BM is not dependent on the 
expression of CXCR4 
(A) Flow cytometric assessment of the level of CXCR4 on mock or CD166KD 
H929 cells (B) 2X107 Mock control or CD166KD H929 cells were IV injected into 
NSG mice. GFP cells were recovered from mouse BM 14h later and the 
expression of CD166 on H929 in peripheral blood and BM were compared flow 
cytometrically.  (C) MFI of CD166 expression on H929 cells. (N = 3 
mice/group/experiment, each assayed individually). Two-way anova, ***P<0.001. 
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Figure 11. Mice bearing CD166KD cells showed delayed disease 
progression and prolonged survival 
(A) 1x104 flow sorted CD166+ or CD166- H929 GFP/luciferase cells were 
injected into NSG mice. 12 weeks post-injection, the mice were injected with D-
Luciferin (Promega, 150mg/Kg mouse) sub-cutaneous and imaged with Berthold 
NightOWL LB 971 in vivo Imaging System (IU School of Medicine) (B-C) 1X105 
Mock control or CD166KD H929 cells were IV injected into NSG mice. (B) 
Human IgA-kappa levels in the serum of individual mice were measured by 
ELISA every two weeks. T-test, *p<0.05. (C) Survival was monitored for a period 
of 220 days and Kaplan-Meier survival curves were plotted. Data are represented 
from 2 pooled experiments (N = 6-8 mice/group/experiment, each assayed 
individually). Long rank test, *p<0.05.  
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Figure 12. Mice bearing CD166KD cells had significantly less bone lesions 
(A-F) 1X105 Mock control or CD166KD H929 cells were IV injected into NSG 
mice. Eight weeks after inoculation, mice were killed. (A) BM cells were flushed 
and GFP-labeled H929 cells were detected with flow cytometry. (B) Tibiae were 
imaged with radiography and representative images are shown. Bone lesions 
area on tibiae from mock group is bigger than those from CD166KD group (white 
arrow). (C) Tibiae were analyzed with micro-CT and trabecular bone volume 
(BV/TV) was analyzed by an analyzer blinded to the experimental groups.  (D-E) 
Mice calvariae were fixed, decalcified and sectioned in a coronal orientation 
posterior to the junction of the sagittal and coronal suture and processed and 
stained with TRAP. (D) TRAP staining of calvariae from mice transplanted with 
mock control H929 cells or CD166KD H929 cells (×20, scale bar=100 μm). (E) 
TRAP+ osteoclasts (stained red, arrowhead) were counted from three non-
overlapping fields per bone under 20 x magnifications. Data are representative of 
2 separate experiments (mean±SEM, N = 6 mice/group/experiment, each 
assayed individually). Student t-test, *p<0.05. (F) Expression of Osteocalcin in 
calvarial cells from mice transplanted with mock or CD166KD H929 cells was 
detected by quantitative PCR relative to GAPDH. 
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Discussion 
 
Interactions between MM cells and cells of the bone marrow microenvironment 
are vital for MM cell growth and bone destruction (90,91). MM is characterized by 
multiple bone lesions along the skeleton (92), indicating that migration of MM 
cells from one site and lodgment in secondary sites is important for MM disease 
progression. In the present study, we have shown that CD166 is expressed on 
both MM cell lines and CD138+ primary BM cells from 4 out of 4 patients.  
 
Our previous studies as well as early and recent studies on CD166 showed that it 
is expressed on cells in the bone marrow microenvironment (93,94).  Using 
homing assays, we showed that CD166+ MM cells preferentially home to the BM 
while knocking down CD166 expression on MM cells impedes cell homing. 
Furthermore, our results indicate that CD166 is critical in directing MM cells 
migrating to the BM as the expression level of CXCR4, which was shown by 
others (84) to mediate MM cells homing the BM did not change when CD166 was 
knocked down in H929 cells (Figure 10A).  These observations, demonstrate for 
the first time that CD166 is involved in MM cells trafficking and suggest that 
CD166 may be critical for MM pathogenesis.  
 
To investigate the possibility of involvement of CD166 in MM pathogenesis, we 
investigated in a mouse model the impact of loss of CD166 expression on 
disease progression. To that effect, we used shRNA constructs to generate 
CD166KD H929 cells and established MM in cohorts of NSG mice using mock or 
55 
CD166KD H929 cells. Our data demonstrated a statistically significant difference 
in the survival of mice harboring mock H929 compared to those in which MM was 
initiated with CD166KD H929 cells. Of interest is that the osteolytic surface to 
bone surface ratio in mice with CD166KD H929 cells was significantly lower than 
that in mice with mock H929 cells suggesting the direct involvement of CD166 in 
MM pathogenesis and the associated bone lytic disease. These data were also 
confirmed by TRAP staining of calvariae and osteoclast cell counting from mice 
in both groups. These results suggest that the level of expression of CD166 on 
MM cells may be a prognostic indicator of the severity of bone lytic disease in 
MM. It should be noted that knocking down CD166 in H929 cells does not alter 
the proliferation kinetics of these cells in vitro (Figure 9) demonstrating that 
CD166 may not be required for the survival, proliferation, or apoptosis of these 
cells, but that it is critical for the interaction of MM cells with other cells in the BM 
microenvironment that also express CD166.  
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Chapter 3. Role of CD166 in the pathobiology of bone lytic disease in MM 
 
Introduction 
 
 The BM microenvironment is crucial for MM disease progression and the 
associated bone lytic disease through supporting MM cell growth and expansion 
by increasing bone destruction through mechanisms that are not yet well-defined 
(91,96). Up to 90% of MM patients develop bone disease, which is associated with 
bone fractures, bone pain and hypercalcemia, not only affecting patients’ quality 
of life, but also their longevity and quality of life. MM bone disease is characterized 
by multiple osteolytic lesions throughout the skeleton.  
 
The basic principle of increased bone resorption in MM is unbalanced bone 
remolding activity with increased bone resorption by osteoclasts and decreased 
bone formation by osteoblasts. MM cells suppress osteoblast differentiation and 
activity and stimulate osteoclast formation and function. The increased osteoclast 
activity further support MM cells survival and proliferation, forming a vicious circle 
between bone destruction and MM disease progression.  
  
MM increases osteoclast activity 
The adherence of MM cells to the BMSC, through multiple adhesion molecules 
and their ligands on MM cells and BMSC, leads to the upregulation of osteoclasts 
activating factors produced by both MM cells and BMSCs. These factors include 
RANKL, M-CSF, IL-6, IL-3, TNFα, TNFβ, macrophage inflammatory protein 
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(MIP)-1α, MIP-β, stromal-cell-derived factor (SDF)-1α/CXCL12 (97-101). 
However, investigations over the last few years have established that the RANKL 
and OPG system plays the most critical role in osteoclastogenesis in MM. 
RANK is a transmembrane molecule belonging to the TNF receptor superfamily. 
It is expressed on osteoclast precursors (102). RANKL is expressed by BMSC or 
osteoblasts (103). Binding to RANKL on osteoclast precursors induce osteoclast 
formation and maturation. RANKL is critical for osteoclastogenesis while RANKL 
or RANK knockout mice are deficient of osteoclasts and develop severe 
osteoporosis.  
 
OPG is also a member of the TNF receptor superfamily and it is a decoy receptor 
of RANKL (104). OPG is expressed by osteoblasts and other cell types. The 
binding of OPG to RANK inhibits RANKL interaction with RANK, thus inhibiting 
osteoclastogenesis. Under normal condition, the RANKL to OPG ratio is very 
low. However, in bone diseases, this ratio becomes either higher or lower than 
normal levels, leading to osteoporosis or osteopetrosis, respectively (105).    
MM cells induced the increased RANKL to OPG ratio by increasing RANKL 
expression and decreasing OPG secretion. The increased ratio favors osteoclast 
formation and activity.  
 
MM decreases osteoblast activity 
The inhibition of osteoblast activity by MM is primarily mediated by direct cell-cell 
contact between MM cells and osteoprogenitors (46). The formation and 
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differentiation of osteoblasts from BMSC depends on the activity of transcription 
factor RUNX2. RUNX2 knockout mice lack osteoblasts or bone formation, 
demonstrating the critical role of RUNX2 in osteoblastogenesis (106). Coculturing 
human MM cells with osteoprogenitors in vitro decreased RUNX2 activity in 
osteoprogenitors and further inhibited osteoblast formation as evidenced by 
reducing the number of colony-forming units (CFU-OBs) formation and 
decreasing the osteoblast differentiation markers, ALP and Ocn (106).  
Soluble factors secreted by MM cells may also inhibit osteoblast differentiation. 
IL-7 has been demonstrated to inhibit RUNX2 promoter activity and IL-7 can 
inhibit bone formation in mice (107). Dickkopf WNT signaling pathway inhibitor 1 
(DKK1) is a secreted Wnt signaling pathway inhibitor of MM cells. It is 
responsible for the suppression of osteoblast formation and bone destruction 
associated with MM (108). 
 
In Chapter 2, we have showed that CD166 is critical for MM cells homing to the 
BM and MM disease progression. In this chapter, we used ex vivo culturing 
system and in vitro assays including ex vivo organ coculture assay to investigate 
whether or not CD166 is involved in MM bone diseases. Our results 
demonstrated that the absence of CD166 expression on MM cells diminished 
their ability to induce bone osteolytic lesions ex vivo and osteoclast formation in 
vitro. We further showed that TRAF6 signaling pathway is indispensable for 
CD166-induced osteoclastogenesis in MM.  
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Materials and Methods 
 
Cells, cell culture, and mice 
 
The H929 human MM cell lines were purchased from ATCC. The OPM2 cell line 
was generously provided by Dr. G. David Roodman (Indiana University School of 
Medicine, Indianapolis, IN). CD138-positive primary myeloma cells from patients 
were kindly provided by Drs. Attaya Suvannasankha and Rebecca Silbermann 
(Indiana University School of Medicine, Indianapolis, IN). MM cells were cultured 
in RPMI 1640 and were supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin and streptomycin. All cells were maintained at 37 ℃ with 5% CO2 air. All 
studies using human cells were approved by the institutional review board of the 
IUSM.  
 
NSG mice, C57BL/6 mice and ALCAM-/- (CD166-/-) mice (10-day old pups) were 
used. Mice were bred and housed in the animal facility at Indiana University. All 
procedures were approved by the Institutional Animal Care and Use Committee of 
the IUSM and followed National Institutes of Health guidelines. 
 
For EVOCA, Calvariae from 10 day old neonatal C57BL/6 mice and global 
ALCAM-/- mice were dissected under sterile conditions as described (109). Half of 
the calvariae was used to coculture with myeloma cells in a-MEM/RPMI1640 50/50 
medium supplemented with 1% P/S for 10 days and the medium was changed 
every 72 h thereafter (Figure 13). When calvariae were cocultured with patient MM 
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cells, a-MEM/RPMI1640 50/50 medium with 1% P/S and 5% Bovine Serum 
Albumin (BSA) was used. For histology, calvariae were removed from culture and 
dipped in PBS then fixed with 10% neutral buffered formalin, decalcified with 10% 
w/v EDTA, embedded with paraffin, sectioned, and stained with hematoxylin and 
eosin. 
 
MM primary BM CD138+ cell selection, flow cytometry and sorting  
 
MM primary BM CD138+ cells were selected by immunomagnetic separation 
(magnetic activated cell sorting, MACS) using anti-CD138 MicroBeads (Miltenyi 
Biotec). Briefly, MM patients’ BM mononuclear cells were enriched using Ficoll-
Paque Premium 1.084 (GE health care). Mononuclear cells were counted and 
incubated with anti-CD138 Microbeads at 10ul microbeads/1x107 cells followed by 
magnetic separation. 
 
BM cell suspensions or MM cell lines were labeled with monoclonal CD166-PE 
antibody (Biolegend). Cells were acquired on an LSRII (BD Biosciences) flow 
cytometer, and events (0.1-2x106) were collected and analyzed with FlowJo.  
CD166+ and CD166- cells were sorted on the BD FACSAria cell sorter from MM 
cell lines and patient CD138+ MM cells after staining with anti-human CD166-PE.   
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In Vitro osteoclast assays 
 
Primary mouse bone marrow monocytes (BMM) were used for in vitro osteoclast 
studies as described (110). BMM were isolated with Ficoll-Paque Premium 1.084 
(GE health care) from total nonadherent bone marrow cells cultured on tissue 
culture dishes for 48 h. BMM were first cultured in α-MEM with 10% FBS and 1% 
P/S and 10ng/ml murine M-CSF (Peprotech) for 3 days and then switched to the 
above media with 50ng/ml murine RANKL (Biolegend) for 7 days in which mock 
control or CD166KD H929 cells were added to the culture at day 3. At the end of 
the culture, H929 cells were washed off with PBS. The adherent cells were fixed 
and stained with TRAP (Sigma-Aldrich). TRAP-positive cells from the whole culture 
in 48-well plate with 3 or more nuclei were counted as osteoclast.  
 
Mice Xenograft human MM model 
 
For intratibial tumor inoculation, 10ul containing 1x105 H929-GFP cells (mock or 
CD166KD) were injected into sub-lethally irradiated NSG mice under anesthesia. 
X-ray of the mice tibiae was performed at 4 and 8 weeks later under anesthesia. 
Mice were euthanized at 9 weeks. Bilateral tibiae were dissected and imaged with 
micro-CT. BM in the tibiae was then flushed and analyzed by flow cytometry.  
 
Radiography and micro-computed tomography (micro-CT) 
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Osteolytic lesions were analyzed by radiography using a Kubtec digital X-ray 
imager with energy range: 10–90 kV and tube current up to 1.0 mA (Kubtec, 
Milford, CT).  Mice were x-rayed in a prone position at 2.7x magnification. 
Osteolytic lesion area was measured by Bioquant image analysis software 
(Bioquant, Nashville, TN). Bone osteolytic lesions were quantified using a 
VIVACT-40 micro-CT system (Scanco Medical, Brüttisellen, Switzerland) at voxel 
size of 15 μm; scanner settings: 55kVp, 145 μA and 350 ms integration time, by 
an observer blinded to the groups. Total bone volume was evaluated from 2mm 
below the most distal layer of the proximal growth plate and spanned 5 mm 
distally along the diaphysis. A threshold of 230 was used to manually delineate 
bone from surrounding soft tissue.  
 
Stimulation of bone marrow monocytes (BMM) with H929 cells and Western 
blotting 
 
BMM cells were plated in 6-well plates in α-MEM supplemented with 10% FBS and 
1% P/S and 10ng/ml murine M-CSF for 3 days. The cells were then serum starved 
for 2 h before stimulation with mock control or CD166KD H929 cells for 30mins. 
H929 cells were washed off with cold PBS on ice. BMM cells were lysed with RIPA 
buffer (Santa Cruz Biotechnology). Total protein was extracted and the extracts 
were subjected to SDS-PAGE and Western blotting. Primary Abs used included 
TRAF6 (Biolegend), phospho-Akt, Akt, (Cell Signaling Technology), phospo-p38, 
p38, IkBα, NFATc1 (Santa Cruz), actin (Sigma-Aldrich). HRP-conjugated 
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secondary Abs (Cell Signaling Technology) were probed and developed with ECL 
solution (Millipore). 
 
Real-time PCR 
 
Total mRNA was extracted using RNeasy or QIAzol (QIAGEN) per the 
manufacturer's protocol and reverse-transcribed using SuperScript II (Invitrogen). 
Quantitative PCR was performed on an ABI7900 using a SYBR Green PCR Core 
Kit (Applied Biosystems). The primers used for quantitative PCR are listed in Table 
3. Relative expression was calculated using the comparative 2−ΔΔCt method, with 
GAPDH as the internal control. 
 
Transfection and infection studies 
 
The lentiviral vectors (pLKO1 vector with hCD166shRNA construct) to knockdown 
(KD) CD166 expression in MM cells was graciously provided by Dr. Helmut 
Hanenberg (Indiana University School of Medicine, Indianapolis, IN). 
To generate lentiviral stocks, lentiviral vectors were transfected into the packing 
cell line 293T using lipofectamine 2000 (invitrogen) according to the 
manufacturer’s instructions. Viral supernatant was collected 48 h after transfection. 
H929 cells were incubated with viral supernatant for 12 h and then cultured in fresh 
RPMI1640 at 37℃ in 5% CO2 air for 72 h. GFP-positive cells were sorted on a BD 
FACSAria cell sorter. 
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Statistical analysis 
 
Each experiment was repeated at least 3 times, and all quantitative data are 
presented as mean ± SEM unless otherwise stated. Statistical differences were 
determined by Student t-test, log-rank test, one-way ANOVA or two-way ANOVA 
with Bonferroni post t-test. Results were considered significantly different for P 
< .05. 
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Table 3. qRT-PCR primers sequences 
 
 
 
 
 
 
Gene Name Forward primer 
sequence (5’ to 3’) 
Reverse primer 
sequence (5’ to 3’) 
GAPDH,mouse AGGAGTATATGC
CCGACGTG 
TCGTCCACATCCAC
ACTGTT 
RUNX2, mouse CGGTCTCCTTC
CAGGATGGT 
GCTTCCGTCAGCGT
CAACA 
RANKL mouse CATCGGGTTCC
CATAAAG 
GAAGCAAATGTTGG
CGTA 
OPG, mouse CCGAGTGTGTG
AGTGTGAGG 
CCAGCTTGCACCAC
TCCAA 
M-CSF, mouse TCCACCGGGAC
GTAGCA 
CCAGTCCAAAGTCC
CCAATCT 
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Figure 13. Schematic representation of ex vivo organ coculture assay 
(EVOCA) 
Calvariae from 10 day old neonatal C57BL/6 mice and global ALCAM-/- mice 
were dissected under sterile conditions as described. Both halves of each 
calvarium were used. Each half was seeded in a cocultured system with 50,000 
myeloma cells in a-MEM/RPMI1640 50/50 medium supplemented with 1% P/S 
for 10 days and the medium was changed every 72 h thereafter.  When calvariae 
were cocultured with patient MM cells, a-MEM/RPMI1640 50/50 medium with 1% 
P/S and 5% BSA was used. 
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Results 
 
CD166 is critical for the pathobiology of bone lytic disease in MM 
 
To further investigate the impact of CD166 on osteolytic lesions associated with 
MM, we used an ex vivo organ culture system designed to allow for both the in 
vitro proliferation of MM cells including those from primary sources and for the 
formation of MM-associated bone lesions. Flow sorted CD166+ or CD166- H929 
cells were cocultured with calvariae from 10 day-old WT or globally CD166KO 
pups for 10 days. At the end of the coculture, the calvariae were processed for 
histological analysis. Mean resorption surface to total bone surface ratio was 
quantified by Bioquant software. These analyses demonstrated that absence of 
CD166 on MM cells (CD166- H929 cells) or bone (CD166-/- calvariae) or both, 
significantly decreased the osteolytic lesions on the calvariae (Figure 14A-B). 
Similar results (Figure 15A-B) were observed when another MM cell line, OPM2 
was used in similar investigations as described above.  
 
Next, we determined whether the absence of CD166 on MM patient cells 
decreased bone osteolytic lesions. In a separate experiment, primary 
CD138+CD166+ or CD138+CD166- MM cells from three patients (Pt) were 
separated by flow cytometric cell sorting (the expression of CD166 on patients’ 
CD138+ cells is shown in Figure 16) and cocultured with calvariae from 10 day-old 
WT or CD166 KO pups for 10 days. Similar to what we observed with MM cell lines, 
the lowest resorption surface to bone surface ratio was observed when 
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CD138+CD166- MM cells were cocultured with CD166KO calvariae (Pt1 Figure 17 
and Pt2, Figure18A) or when MM cells were cocultured with CD166KO calvariae 
(Pt3, Figure18B).  
 
To confirm these ex vivo observations in vivo, NSG mice were intratibially 
inoculated with mock or CD166KD H929 cells. Radiographic analysis revealed that 
mice receiving mock H929 cells developed osteolytic lesions 4 weeks after tumor 
inoculation. The bone deteriorated further through the course of 8 weeks. On the 
contrary, although tibiae from CD166KD H929 inoculated mice showed osteolytic 
lesions at 4 weeks, these lesions worsened to a lesser extent than that observed 
in the mock group over the next 4 week period (Figure 19A). In agreement, micro-
CT images at 9 weeks demonstrated that mock H929 cells induced much more 
sever lesions in the tibiae compared to CD166KD cells (Figure 19B). Both 
trabecular thickness (Figure 19C) and trabecular bone volume fraction (Figure 19D) 
at 9 weeks post-inoculation were significantly decreased in the tibiae from mice 
receiving mock H929 cells. Flow cytometric analysis of the BM from the inoculated 
tibiae did not reveal differences in the percentage or cell number between mice 
inoculated with mock or CD166KD H929 cells (Figure 20A-B). However, 2 out of 5 
contralateral tibiae in the mock group had detectable H929 cells (>0.1% by flow 
cytometric analysis). In contrast, none of the 6 contralateral tibiae of mice 
inoculated with CD166KD H929 cells had detectable GFP+ cells (Figure 20C). 
These results are consistent with our homing assay data that CD166 is critical for 
MM cells trafficking in the BM. 
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Figure 14.  EVOCA assay with H929 cells 
(A-B) EVOCA was used to examine the effect of CD166 expression on myeloma 
osteolytic lesions. Calvariae were fixed, decalcified, sectioned and processed for 
H&E staining. Bone resorption (black arrow) on the mice calvariae were analyzed 
from three non-overlapping fields per bone under 20 x magnifications. The 
quantitative representation of EVOCA assay was performed by measuring and 
calculating resorption surface to BS ratio with Bioquant software 2014. (A) H&E 
staining of Calvariae from WT or CD166KO pups cultured with flow sorted 2x104 
CD166+ or CD166- H929 cells for 10 days (×20, scale bar=100 μm). (B) 
Quantitative representation of EVOCA assay with H929; Data represent 3 
separate experiments done in triplicates for each group are expressed as mean± 
SEM, two-way anova, *p<0.05. 
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Figure 15.  EVOCA assay with OPM2 cells 
(A-B) EVOCA was used to examine the effect of CD166 expression on myeloma 
osteolytic lesions. Calvariae were fixed, decalcified, sectioned and processed for 
H&E staining. Bone resorption (black arrow) on the mice calvariae were analyzed 
from three non-overlapping fields per bone under 20 x magnifications. The 
quantitative representation of EVOCA assay was performed by measuring and 
calculating resorption surface to BS ratio with Bioquant software 2014. (A) H&E 
staining of Calvariae from WT or CD166KO pups cultured with flow sorted 2x104 
CD166+ or CD166- OPM2 cells for 10 days (×20, scale bar=100 μm). (B) 
Quantitative representation of EVOCA assay with H929; Data represent 3 
separate experiments done in triplicates for each group are expressed as mean± 
SEM, two-way anova, *p<0.05.  
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Figure 16.  Flow cytometric analysis of CD166 expression levels on 3 MM 
patients’ CD138+ cells in EVOCA assay  Black line = isotype control; red line = 
sample 
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Figure 17.  EVOCA assay with patient 1 BM CD138+ cells  
EVOCA was used to examine the effect of CD166 expression on myeloma 
osteolytic lesions. Calvariae were fixed, decalcified, sectioned and processed for 
H&E staining. Bone lesions on the mice calvariae were analyzed from three non-
overlapping fields per bone under 20 x magnification. The quantitative 
representation of EVOCA assay was performed by measuring and calculating 
resorption surface to BS ratio with Bioquant software 2014. (A) H&E staining of 
Calvariae from WT or CD166KO pups cultured with flow sorted 2x104 
CD138+CD166+ or CD138+CD166- MM patient cells for 10 days. (B) 
Quantitative representation of EVOCA assay in (A). Two-way anova, *p<0.05. 
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Figure 18. EVOCA assay results with patients 2 and 3 
EVOCA was used to examine the effect of CD166 expression on myeloma 
osteolytic lesions. Calvariae were fixed, decalcified, sectioned and processed for 
H&E staining. Bone lesions on the mice calvariae were analyzed from three non-
overlapping fields per bone under 20 x magnification. The quantitative 
representation of EVOCA assay was performed by measuring and calculating 
resorption surface to BS ratio with Bioquant software 2014. H&E staining of 
Calvariae from WT or CD166KO pups cultured with flow sorted 2x104 
CD138+CD166+ or CD138+CD166- MM patient cells for 10 days. (A-B) 
Quantitative representation of EVOCA assay with Pt2 and Pt3 cells. Two-way 
anova, *p<0.05. 
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Figure 19. Absence of CD166 on MM cell leads to less bone osteolytic 
lesions 
(A) Representative radiographic images of tibiae from mice inoculated with mock 
or CD166KD H929 cells at 4 weeks and 8 weeks after inoculation. Bone lesion 
areas are indicated with white arrow. (B) Nine weeks after inoculation, mice were 
euthanized and tibiae were collected and scanned using micro-computed 
tomography (micro-CT) for 3D reconstruction. Bones from 3 representative mice 
are shown. (C) Trabecular thickness Tb.Th and (D) trabecular bone volume 
(BV/TV fraction) were determined by micro-CT readings. n=5-6/group, mean± 
SEM, Two-way anova, *p<0.05. 
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Figure 20.  BM analysis of mice intratibially inoculated with mock or 
CD166KD H929 cell 
NSG mice were inoculated with 105 mock or CD166KD H929 cells in the right 
tibia. After 9 weeks, mice were euthanized and both tibiae were collected. After 
scanning both bones for micro-computed tomography for 3D reconstruction 
(shown n Figure 4B), BM was harvested from both tibiae and kept separate. BM 
counts in right and left tibiae of experimental mice and from control mice are 
shown in (A). (B) The percentage of GFP labeled H929 in the BM of the right tibia 
was analyzed with flow cytometry. (C) BM cells were counted with 
hemocytometer and the number of H929 cells in the right tibiae were calculated. 
n=5-6/group, mean± SEM, student t-test, *p<0.05, NS=no significant difference. 
(D) Representative flow cytometry analysis of BM from left tibiae. 2 out 5 left 
tibiae from mock control group showed detectable GFP+ MM cell.  However, 
none of the 6 left tibiae from CD166KD group analyzed by flow cytometry 
contained detectable (>0.1% by flow cytometric analysis) GFP+ MM cells. 
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CD166 expression on MM cells suppresses RUNX2 expression in 
osteoprogenitors 
 
To examine how CD166 induces bone osteolytic lesions in MM, we first explored 
the mechanisms involved in MM-induced osteoblast suppression. BMSC were 
isolated from the BM of WT or CD166KO mice as described before (111) and 
were then cocultured with CD166KD or mock control H929 cells for 48h. H929 
cells were washed off by cold PBS and RNA was isolated from BMSC. Real-time 
PCR results revealed that gene expression of RUNX2, a critical transcription 
factor in osteoblastogenesis, was significantly suppressed when CD166 was 
present in the culture. (Figure 21). 
 
CD166 expression on MM cells increases RANKL: OPG ratio in both BMSC 
and cells in calvarial bone 
 
We then examined the mechanisms involved in MM-induced osteoclast 
activation. We first measured by real-time PCR analysis gene expression levels 
of RANKL and OPG in BMSC isolated from the BM of WT or CD166KO mice. 
BMSC were then cocultured with CD166KD or mock control H929 cells for 24h. 
H929 cells were washed off by cold PBS and RNA was isolated from BMSC. 
Gene analysis showed that RANKL /OPG ratio, an important indicator for 
osteoclastogenic activity (112), was significantly decreased when CD166 was 
absent from either MM cells (CD166- H929 cells) or from BMSC cells (CD166-/- 
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BMSC) (Figure 22A). Similar result was observed when BMSC were cocultured 
with another MM cell line, OPM2 (Figure 22B). 
 
We next measured by real-time PCR analysis gene expression levels of RANKL 
and OPG in calvarial cocultured with CD166KD H929 or mock control H929 cells 
for 7 days. At the end of the coculture, H929 cells were washed off by cold PBS 
and calvariae were subjected to RNA isolation. Gene analysis showed that 
RANKL /OPG ratio, was significantly decreased when CD166 was absent from 
either MM cells (CD166- H929 cells) or from bone cells (CD166-/- calvariae) 
(Figure 23A). We also examined gene expression of M-CSF, another critical 
molecule on osteoclastogenesis, and found no significant difference (Figure 
23B). 
 
CD166 expression on MM cells promotes osteoclast formation in vitro 
 
We used a previously described osteoclast differentiation assay (113) to 
measure osteoclastogenesis by bone marrow-derived macrophages (BMM) from 
WT or CD166KO mice cultured with mock control or CD166KD H929 cells. The 
degree to which osteoclasts were generated in culture was visibly reduced in 
cultures where either expression of CD166 on H929 cells was blocked or was 
genetically abrogated on BMM (Figure 24A). Importantly, quantification of 
osteoclast formation by assessing TRAP+ cells (≥3 nuclei) demonstrated that the 
number of TRAP+ cells  was significantly compromised in cultures where CD166 
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was absent from H929 cells or when BMM were collected from CD166KO mice 
(Figure 24B).  
 
CD166 up-regulates key signaling pathways involved in osteoclastgenesis 
in MM through the regulation of TRAF6 
 
To further delineate the mechanisms involved in CD166-induced 
osteoclastogenesis in MM, we starved BMM for 2h then stimulated these cells 
with mock control H929 or CD166KD H929 cells for 30mins. BMM were then 
subjected to western blot analysis for Tumor necrosis factor (TNF) receptor 
associated factor 6 (TRAF6), a TNF receptor associated factor that plays a 
critical role in the signal transduction pathways in osteoclastogenesis (114). Our 
results indicate that while BMM from WT mice upregulated TRAF6 expression 
upon stimulation with control H929 cells, WT BMM stimulated by CD166KD H929 
or BMM from CD166-/- mice failed to upregulate TRAF6 expression (Figure 25A, 
B). In MM, TRAF6 mediates osteolytic bone lesions through the regulation of 
several downstream signaling pathways, including Akt, NFkB and p38MAPK 
(115), (116). So we next examined the activation of these downstream pathways 
of TRAF6 in BMM treated as described above. Western blot analysis 
demonstrated that the absence of CD166 on H929 or BMM decreased phospho 
AKT, phospho p38 and phospho IkBa levels (Figure 25A, C-E), indicating that 
loss of CD166 downregulates AKT, CD38MAPK and NFkB activation and most 
likely suppresses osteoclastogenesis.   
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Figure 21.  RUNX2 gene expression analysis on BMSC treated with H929 
cells   
RNA from BMSC cells cocultured with H929 cells (as indicated) for 48h before 
removal of the H929 cells and RNA isolation from the BMSC cells. Expression of 
RUNX2 was detected by quantitative PCR normalized to GAPDH and the “WT 
BMSC alone” sample. Two-way anova, *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
90 
Figure 22.  RANKL and OPG gene analysis on BMSC cocultured with H929 
cells or OPM2 cells  
(A) RNA from BMSC cells cocultured with H929 cells (as indicated) for 24h 
before removal of the H929 cells and RNA isolation from the BMSC cells. 
Expression of RANKL and OPG was detected by quantitative PCR normalized to 
GAPDH and the “WT BMSC” sample. RANKL: OPG ratio was shown. (B) RNA 
from BMSC cells cocultured with H929 cells (as indicated) for 24h before removal 
of the H929 cells and RNA isolation from the BMSC cells. Expression of RANKL 
and OPG was detected by quantitative PCR normalized to GAPDH and the “WT 
BMSC” sample. RANKL: OPG ratio was shown. Two-way anova, *p<0.05. 
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Figure 23.  Osteoblastic gene analysis of calvariae cocultured with H929 
cells 
(A) RNA from calvairal cocultured with H929 cells (as indicated) for 7 days before 
removal of the H929 cells and RNA isolation from the calvarial. Expression of 
RANKL and OPG was detected by quantitative PCR relative to GAPDH and the 
“WT calvairal alone” sample. RANKL: OPG ratio was shown. (B) RNA from 
calvariae cocultured with H929 cells (as indicated) for 7 days were isolated after 
removal of the H929 cells. Expression of M-CSF was detected by quantitative 
PCR relative to GAPDH. Two-way anova, *p<0.05. 
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Figure 24.  Osteoclast formation assay of BMM cells cocultured with mock 
or CD166KD H929 cells  
(A) Non-adherent BM derived monocyte/macrophage from WT or CD166KO 
mice were cultured at a density of 65,000/cm2 in α-MEM and supplemented with 
10% FBS in the presence of recombinant mouse M-CSF (10 ng/ml) for 3 days to 
get adherent BMM. BMM were then cultured in α-MEM and supplemented with 
10% FBS in the presence of recombinant mouse M-CSF (10 ng/ml) and RANKL 
(50ng/ml) for 7 days and mock H929 or CD166KD H929, followed by TRAP 
staining. (B)TRAP-positive MNCs from the whole culture were scored under a 
microscope. Data represent 3 separate experiments done in triplicates for each 
group are expressed as mean± SEM, Two-way anova, *p<0.05. 
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Figure 25. Absence of CD166 expression on MM cells downregulates key 
signaling pathways in osteoclastogenesis.   
BMM were derived from bone marrow cells by culturing in the presence of M-
SCF (10 ng/ml) for 3 days. (A-E) BMM were serum starved for 2h before 
exposure to mock H929 or CD166KD H929 for 30mins. H929 cells were washed 
off with cold PBS before the use of BMM in Western Blot analyses. BMM were 
then subjected to RIPA lysis and analyzed for the indicated proteins. Whole cell 
extracts were subjected to Western blot analysis with specific antibodies as 
indicated. Quantitative densitometry of the expression of the indicated proteins 
was normalized to actin protein expression. Data were collected from three 
separate observations and are expressed as mean± SEM. Two-way anova, 
*p<0.05. 
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Figure 26.  Absence of CD166 expression on MM cells NFATc1 in 
osteoclastogenesis 
BMMs were derived from bone marrow cells by culturing in the presence of M-
SCF (10 ng/ml) for 3 days. (A-B) BMM were cultured with mock H929 or 
CD166KD H929 in the presence of M-CSF (10 ng/ml) and RANKL (50ng/ml) for 
the indicated time. Whole cell extracts were subjected to Western blot analysis 
with specific Abs as indicated. Quantitative densitometry of the expression of the 
indicated proteins was normalized to actin protein expression. Data were 
collected from three separate observations and are expressed as mean± SEM. 
Two-way anova, *p<0.05.  
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Nuclear factor of activated T cells (NFAT)c1 is the key modulator in 
osteoclastogenesis (117). We further examined NFATc1 expression during 
osteoclastogenesis in our model. NFATc1 expression was strongly attenuated by 
the absence of CD166 expression on either H929 cells or BMMs (Figure 26A-B). 
Thus, CD166 regulate NFATc1 expression through regulating key signaling 
pathways during CD166 induced osteoclastogenesis in MM.  
 
Discussion 
 
Bone disease is a key complication in MM. Increased bone resorption in MM is 
due to osteoblast inhibition and osteoclast activation.  
 
To determine the pathophysiologic effects of CD166 expression on MM bone 
disease, we used a novel EVOCA assay and found that CD166 can cause MM 
cells to induce bone destruction. Furthermore, the absence of CD166 on any cell 
type present in the EVOCA culture diminished this bone lytic disease. CD166 is a 
member of the immunoglobulin super family with 5 extracellular domains that can 
mediate homophilic (CD166-CD166) interactions (118). Therefore, the 
biochemical characteristic of CD166 and the results from the EVOCA assay 
suggest that homophilic interactions between MM cells and osteoblasts or other 
osteolineage cells expressing CD166 are critical for the progression of bone lytic 
disease.  The fact that identical results were obtained when cells from two 
different MM cell lines and primary cells from 3 different patients were used in 
this assay, suggest that expression of CD166 or lack thereof is physiologically 
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relevant to MM. Bone remodeling is balanced by bone formation by osteoblasts 
and bone resorption by osteoclasts. However, this balance is broken or perturbed 
in the event of bone destruction (119,120). Therefore, it is possible that the 
change in bone remodeling observed in MM may result from CD166-mediated 
suppression of osteoblastogenesis or enhancement of osteoclastogenesis. Using 
in vitro assays, we demonstrated that expression of CD166 on MM cells 
promoted the repression of RUNX2, the key transcription factor in osteoblasts 
differentiation from BM-derived MSC (121). On the other hand, loss of CD166 on 
MM cells reduced the osteoclastogenic potential of BM-derived monocytes when 
these two cell types were co-cultured together suggesting that 
osteoclastogenesis was supported by CD166+ MM cells. In determining the 
molecular mechanisms underlying the CD166+ MM cell regulation of osteoclast 
formation, we observed that CD166 expression stimulated overexpression of 
RANKL while it failed to affect gene expression of OPG, an inhibitor of 
osteoclastogenesis, resulting in an increased RANKL: OPG ratio. We did not 
detect any significant difference in the gene expression of MSCF, suggesting the 
selective regulation of RANKL of CD166. Also this result is consistent with 
previous studies showing that increased RANKL: OPG ratio is the most important 
factor affecting osteoclastogenesis in MM (122). These observations implicate 
CD166 in the regulation of osteoclastogenesis through upregulation of RANKL 
and possibly downregulation or inhibition of OPG.  
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To further investigate how these effects are mediated by CD166, we examined 
the possible signaling pathways and revealed a possible novel positive regulatory 
pathway involving CD166-TRAF6 mediated osteoclast formation. Previous 
investigations demonstrated that TRAF6 is regulated by RANKL-RANK signaling 
pathway in osteoclastogenesis (49,123). Our studies documented an 
upregulation of TRAF6 in osteoclast precursors when these cells were stimulated 
by CD166+ MM cells. However, since we did not use RANKL for the stimulation, 
our study, for the first time, indicates that CD166 may regulate TRAF6 directly in 
osteoclastogenesis, suggesting that inhibition of CD166 may represent an 
effective way to control bone lytic disease in MM. Furthermore, we showed that 
the downstream signals of TRAF6, AKT, p38 and NFkB are downregulated by 
the absence of CD166 on MM cells. NFATc1, the important transcription factor in 
osteoclastogenesis, was also shown to be downregulated in the absence of 
CD166 from either MM cells or osteoclast precursors. However, further studies 
are needed to investigate the detailed mechanisms by which CD166 regulates 
RANKL and TRAF6 signaling pathways. 
 
In conclusion, our data implicate CD166 in the progression of MM in vivo and 
suggest that this molecule is intimately involved in the pathogenesis of MM. That 
CD166 is a functional molecule that impacts HSC function and the competence 
of the normal hematopoietic niche, has been recently documented by our 
laboratory (78). Therefore, the question arises whether CD166 is expressed on 
MM initiating cells and whether this marker identifies a group of MM stem cells. 
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Given the involvement of CD166 in the pathophysiology of MM, CD166 could be 
a potential target for inhibiting the MM-induced osteolytic disease as well as 
tumor progression. 
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Chapter 4. Future Directions 
 
The work presented here identified a critical role of CD166 in MM disease 
progression. CD166 is important for MM cells homing to the BM, enhancing 
disease progression and bone osteolytic diseases. Based on our findings, 
several possible future avenues should take and they are described in the 
following: 
 
CD166 identifies MM stem cells 
 
Despite therapeutic advances, MM remains incurable due to relapse and 
therapy-refractory disease. Persistence of drug-refractory MMSC provides a 
possible explanation for this clinical outcome. Targeting these cells is therefore 
appealing in MM therapy. Previously, our laboratory has demonstrated that 
CD166 is a key functional molecule on both human and murine HSC and HSC 
niche cells and that CD166+ fractions of murine and human repopulating HSC 
sustain robust long-term engraftment (78). Interestingly, MSC and osteoblasts, 
two critical components of the hematopoietic niche, also express CD166 (124). 
MM is a plasma cell malignancy in the BM. As a niche-dependent malignancy, 
and the cross-talk between MM cells and their BM niche is important for MM 
progression. Our current observations demonstrate that the interactions between 
MM cells and BM niche cells through CD166 is critical for MM disease 
progression and MM associated bone diseases. CD166+ MM cells home 
preferentially to the BM of NSG mice and cause more severe osteolytic lesions in 
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vivo. CD166 has been used to identify cancer stem cells in several other 
cancers, such as colorectal cancer (71), non-small cell lung cancer (81). Thus it 
is warranted and feasible to investigate whether CD166 is a possible marker for 
MMSC. 
 
Matsui and colleagues identified a composite phenotype of MMSC as 
CD45+CD38+CD19+CD27+CD34-CD138- (59,60,125). They showed that 
CD34+CD19+CD138- but not their CD138+ counterpart MM cells were able to 
recapitulate MM in NOD-SCID mice. In our preliminary studies, when we used 
“Matsui” parameters to examine a newly diagnosed MM patient sample for the 
expression of CD166 on putative MMSC,  about 30% of CD45+CD34-CD138-
CD38+CD19+ cells were also CD166+ (Figure 27A), demonstrating that CD166 
may identify a subset of MMSC. In addition, when we analyzed the MM cell line 
H929 (Figure 26B), we also found a similar expression level of CD166. These 
results indicate that both primary MM cells and the H929 MM cell line share a 
CD166+ population of putative MMSC. Future studies should investigate whether 
or not  limiting number of CD166+ cells from primary patients’ samples or MM 
cell lines can initiate MM in mice models.  
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Figure 27.  Primary MM cells and H929 share the same group of 
phenotypically defined putative MMSC expressing CD166  
(A). BM cells from a MM patient were stained with “Matsui” markers and 
analyzed for CD166 expression on CD45+ CD38+CD19+CD27+CD34-CD138- 
cells. (B). CD166 expression on CD38+CD138- H929 cells. 
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Blocking CD166 with CD166 neutralizing antibody to abrogate disease 
progression 
 
Antibody-based treatment in cancer therapy has been previously pursued in the 
last 2 or 3 decades with relative success (126-128).  Monoclonal antibodies have 
great potential in the diagnosis and treatment of diseases (129). The 
mechanisms of action of the antibody therapy include direct tumor cell killing, 
immune-mediated tumor cell killing and vascular and stromal cell ablation (130).  
Although we did not observe any difference of the growth kinetics between mock 
H929 and CD166KD H929 cells (Figure 9), using anti-CD166 antibody to treat 
the H929 and 8226 MM cells every day for 5 days indicate that anti-CD166 
antibody significantly inhibit the MM cell growth in vitro (Figure 28).  
 
Recently, a CD166 neutralizing antibody fragment (single chain variable 
fragment) scFv173 has been shown to reduce cancer cell invasion and tumor 
growth in a breast cancer model (131). Since our findings demonstrated that 
CD166 is highly expressed on MM cells, it would be critical to know whether or 
not scFv173 can inhibit MM cell homing to the BM and further delay disease 
progression of MM.  
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Determine with more details and particularly in the human system the role 
of CD166 in bone remodeling in MM 
 
Bone remodeling in MM patients is broken to favor osteoclastogenesis while 
inhibiting osteoblastogenesis. Impaired osteoblasts development and bone 
formation contribute significantly to the osteolytic bone lesions associated with 
MM (132). In the present study, we have provided clear evidence that the 
expression of CD166 on MM cells downregulates RUNX2 gene expression on 
osteoblast precursors, indicating that MM cells may inhibit osteoblastogenesis of 
stromal cells in MM through the expression of CD166. However, the exact 
mechanisms behind this are not clear. Work by other groups indicate that cell-to-
cell contact between stromal cells and MM cell are important for osteoblast 
activity inhibition (46,133). Further studies should explore whether the direct 
interactions between MM cells and osteoblast precursors through CD166 are 
critical for the osteoblast inhibition and the downstream signaling pathways 
through which the expression of CD166 on MM inhibits osteoblastogenesis and 
osteoblast functions.  
 
Our result in the osteoclastogenesis assay (Figure 24) that the presence of 
CD166 on BMM cells contributes to the osteoclastogenesis in MM is striking. We 
also demonstrate that CD166 mediates TRAF6 and its downstream signaling 
pathways in osteoclastogenesis in MM. However, all of our current results are 
obtained with the murine system. Further studies should focus on setting up 
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experiments with human cells to examine the effects of MM cells on osteoclast 
activity.  
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Figure 28.  Anti-CD166 antibody inhibits MM cell growth 
(A-B) H929 (A) or 8226 (B) were plated at 1.3x104/well in 48 well-plate. Anti-
CD166 antibody or isotype control were added to the well at 10ul/well every day 
for 5 days. Cell growth was quantified by counting the cell number with 
hemocytometer on days 1, 3 and 5.  Two-way anova, *p<0.05. 
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